Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Adneuris Therapeutics presents novel data on lead candidate, cebranopadol to treat moderate-to-severe acute pain at PAINWeek 2026
1+ day, 18+ hour ago (249+ words) Monmouth Junction, New Jersey Saturday, Septembe... Adneuris Therapeutics presents novel data on lead candidate, cebranopadol to treat moderate-to-severe acute pain at PAINWeek 2026 Adneuris Therapeutics, a wholly owned subsidiary of Tris Pharma advancing a new kind of pain medicine, announced novel…...
Plethora of options means tough decisions for massive cuff tears
2+ day, 1+ hour ago (1501+ words) According to published literature, rotator cuff tears are one of the most common musculoskeletal injuries, affecting 20% to 40% of the population, with the prevalence increasing with age. If left untreated, research has shown that about 30% of massive rotator cuff tears can…...
Osteoarthritis, IVDD & Tendon Injury: Cloud-Clone Primary Cells B
3+ day, 6+ hour ago (265+ words) ridge Musculoskeletal In vitro Model Gaps The National Law Review Osteoarthritis, IVDD & Tendon Injury: Cloud-Clone Primary Cells Bridge Musculoskeletal In vitro Model Gaps High-quality primary cell resources narrow the translational divide between laboratory in-vitro findings and clinical reality HUSTON, TX,…...
Adneuris Therapeutics Presents Novel Data on Lead Candidate, Cebranopadol for the Treatment of Moderate-to-Severe Acute Pain at PAINWeek 2026
2+ day, 19+ hour ago (261+ words) Adneuris unveiled new abuse potential data demonstrating that cebranopadol's abuse potential may be lower than that of Schedule II and Schedule IV pain drugs, further differentiating its dual NOP/MOP mechanism from drugs like oxycodone. The Phase 3 ALLEVIATE studies met…...
Letter to the editor: Improving treatment of pain
3+ day, 7+ hour ago (310+ words) Some years ago, I stood in my office facing a terrifying moment: A pain patient had brought a gun to his appointment. I know firsthand the horror of being targeted by people navigating the exhausting burden of chronic suffering. This…...
Allegro’s Hydrocelin significantly improves knee osteoarthritis pain and function in clinical trial
4+ day, 5+ hour ago (635+ words) daily-tribune.com - Nanotechnology-based injection significantly improved knee pain and function with favorable safety and efficacy sustained over 6 months following a single administration - Feasibility trial in Belgium completed recruitment ahead of schedule with last patient treated; three-month data from study are…...
Breaking the opioid paradigm: Can we separate pain relief from addiction?
4+ day, 7+ hour ago (755+ words) Pain medicine has long confronted a seemingly unavoidable pharmacologic bargain: the drugs most capable of relieving severe pain could also produce euphoria, physical dependence, respiratory depression, and, in vulnerable individuals, addiction. Much of America's response to the opioid crisis has…...
Nanochon Performs First Case in the Chondrograft™ First-in-Human Clinical Study
4+ day, 16+ hour ago (402+ words) WASHINGTON--(BUSINESS WIRE)--Nanochon, a medical device company developing Chondrograft™, a novel 3D-printed patented implant for the treatment of articular cartilage defects of the knee, today announced the successful treatment of the first patient in its First-in-Human (FIH) clinical study....
Vasoactive intestinal peptide promotes cartilage formation and modulates
4+ day, 18+ hour ago (11+ words) osteoarthritis mediators Bioengineer.org...